Comparison of Efficacy and Safety of Topical 1% Butenafine and Topical 1% Ciclopirox Olamine in the Treatment of Tinea Pedis and Evaluation of the Effects on the Quality of Life of These Treatmens: A Randomized Single-Blind Trial

Objective: The aim of the study is to compare efficacy and safety of topical 1% butenafine and topical 1% ciclopirox olamine in tinea pedis and to evaluate effects of these treatments on quality of life.\udMethods: We conducted a randomized controlled trial on 80 patients with tinea pedis between May 2014 and May 2015. Of 80 patients, 40 were treated with 1% butenafine cream and 40 were treated with 1% ciclopirox olamine cream for one month. Clinical characteristics, Dermatology Life Quality Index (DLQI) scores, Physician’s Global Assessment (PhGA), and Patient’s Global Assessment were recorded. \udResults: Forty patients (21 male, 19 female) on butenafine therapy and 40 patients (15 male, 25 female) on ciclopirox olamine therapy were enrolled in the study. Both treatments significantly improved the clinical signs and symptoms, but no significant difference was found between the groups (p>0.05). The DLQI scores decreased significantly after the treatments in both groups. The recurrence was observed only in two patients from ciclopirox olamine group. \udConclusion: Topical butenafine and ciclopirox olamine had similar high efficacy and safety in the treatment of tinea pedis. In addition, both two drugs had positive improvement on quality of life of the patients